Immunine (Human Coagulation Factor Ix)

Human Coagulation Factor IX participates in the intrinsic pathway of blood coagulation. When infused, it combines with activated factor VIII to form the tenase complex, which converts factor X to Xa, leading to thrombin generation and fibrin clot formation, thereby restoring normal hemostasis.

The dosage of Immunine is individualized. A qualified prescriber determines the amount and frequency based on the patient’s factor IX activity level, severity of bleeding, body weight, and clinical situation. Dosing instructions are provided on the prescription label.

Safety data for Immunine in pregnancy and lactation are limited. The decision to use the product should be based on a risk‑benefit assessment by the treating physician, considering the potential need for clotting factor replacement in the mother and the lack of definitive fetal safety information.

To request Immunine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Immunine is a recombinant human factor IX concentrate, offering high purity and low risk of viral transmission compared with plasma‑derived products. Compared with extended‑half‑life factor IX molecules, Immunine has a standard half‑life, requiring more frequent dosing but providing a well‑established safety profile.

Immunine must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If temperature excursions occur, discard the product according to the supplier’s guidelines.

Immunine is given by intravenous infusion. The healthcare professional prepares the sterile solution according to aseptic technique, selects an appropriate infusion rate, and monitors the patient for any adverse reactions during and after the administration.

The most serious risks include the development of neutralising antibodies (inhibitors) that reduce efficacy, severe allergic reactions such as anaphylaxis, and rare thrombotic events. Patients should be monitored closely for signs of these complications, especially after the first few infusions.

Immunine is contraindicated in individuals with known hypersensitivity to human factor IX products or any of the excipients in the formulation. Patients with a history of severe allergic reactions to clotting factor concentrates should avoid its use.